Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enliven Therapeutics (ELVN) Other Accumulated Expenses (2022 - 2026)

Enliven Therapeutics has reported Other Accumulated Expenses over the past 5 years, most recently at $107000.0 for Q1 2026.

  • Quarterly results put Other Accumulated Expenses at $107000.0 for Q1 2026, down 26.71% from a year ago — trailing twelve months through Mar 2026 was $107000.0 (down 26.71% YoY), and the annual figure for FY2025 was $351000.0, up 72.06%.
  • Other Accumulated Expenses reached $107000.0 in Q1 2026 per ELVN's latest filing, down from $351000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $548000.0 in Q1 2023 and bottomed at $63000.0 in Q2 2025.
  • Median Other Accumulated Expenses over the past 5 years was $317000.0 (2023), compared with a mean of $284285.7.
  • Peak annual rise in Other Accumulated Expenses hit 72.06% in 2025, while the deepest fall reached 78.35% in 2025.
  • Over 5 years, Other Accumulated Expenses stood at $447000.0 in 2022, then dropped by 18.57% to $364000.0 in 2023, then tumbled by 43.96% to $204000.0 in 2024, then soared by 72.06% to $351000.0 in 2025, then tumbled by 69.52% to $107000.0 in 2026.
  • Business Quant data shows Other Accumulated Expenses for ELVN at $107000.0 in Q1 2026, $351000.0 in Q4 2025, and $86000.0 in Q3 2025.